{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:05:09Z","timestamp":1784009109387,"version":"3.55.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Advances in immunotherapy for acute myeloid leukemia (AML) have revealed critical gaps in selection of appropriate preclinical models. Conventional cytotoxic and targeted therapies could be tested in relatively straightforward systems. Immunotherapies are inherently distinct from conventional therapies, as their activity is shaped by dynamic, context-dependent interactions between leukemic cells, immune effectors, and the bone marrow microenvironment that are difficult to replicate outside the patient. Failure to recapitulate these interactions may limit the clinical translatability of promising results. Recognizing these shortcomings, the field has moved through several generations of modeling platforms. Existing platforms capture distinct but incomplete aspects of AML biology:\n                    <jats:italic>in vitro<\/jats:italic>\n                    systems offer control but lack immune context, syngeneic models provide intact immunity but limited human relevance, patient-derived xenograft (PDX) models preserve patient biology but lack immunity, and humanized models partially integrate both but remain constrained. In this review, we trace the development of these systems and use that trajectory to build a practical framework for model selection in AML immunotherapy research. Translational relevance depends on selecting preclinical models that align with the specific therapeutic question, rather than relying on availability or perceived complexity. To operationalize this, we propose a mechanism-driven framework that maps therapeutic mechanisms to the most appropriate biological contexts across preclinical platforms. This framework progresses sequentially from controlled mechanistic studies to\n                    <jats:italic>in vivo<\/jats:italic>\n                    validation, guiding model selection at each stage. Instead of prioritizing any single system, it emphasizes a complementary, question-driven approach that leverages the distinct strengths of each model while accounting for their limitations.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1871786","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:39:33Z","timestamp":1784007573000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Aligning preclinical AML models with immunotherapy development: principles for model selection"],"prefix":"10.3389","volume":"17","author":[{"given":"Efe","family":"Karaca","sequence":"first","affiliation":[{"name":"Division of Transplantation and Cellular Therapy Sylvester Comprehensive Cancer Center, Department of Medicine, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar Ataca","family":"Atilla","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy Sylvester Comprehensive Cancer Center, Department of Medicine, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"Ankara University Stem Cell Institute, Ankara University Graduate School of Health Sciences","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy Sylvester Comprehensive Cancer Center, Department of Medicine, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erden","family":"Atilla","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy Sylvester Comprehensive Cancer Center, Department of Medicine, Miller School of Medicine, University of Miami","place":["Miami, FL, United States"]},{"name":"GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"New Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01697-9","article-title":"A primary hierarchically organized patient-derived model enables in depth interrogation of stemness driven by the coding and non-coding genome","volume":"36","author":"Boutzen","year":"2022","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra061808","article-title":"Cancer stem cells","volume":"355","author":"Jordan","year":"2006","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-696039","article-title":"Therapeutic targeting of acute myeloid leukemia stem cells","volume":"129","author":"Pollyea","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/nejmra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","article-title":"The bone marrow microenvironment mechanisms in acute myeloid leukemia","volume":"9","author":"Pimenta","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.158","article-title":"AML xenograft efficiency is significantly improved in NOD\/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3","volume":"24","author":"Wunderlich","year":"2010","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120925","article-title":"An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging","volume":"10","author":"Vick","year":"2015","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/genes10080614","article-title":"A critical review of animal models used in acute myeloid leukemia pathophysiology","volume":"10","author":"Skayneh","year":"2019","journal-title":"Genes (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.3390\/bioengineering10101228","article-title":"Immunotherapy in acute myeloid leukemia: a literature review of emerging strategies","volume":"10","author":"Guarnera","year":"2023","journal-title":"Bioeng (Basel)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402740","article-title":"FLT3 mutations in acute myeloid leukemia cell lines","volume":"17","author":"Quentmeier","year":"2003","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt007","article-title":"The clinical relevance of cancer cell lines","volume":"105","author":"Gillet","year":"2013","journal-title":"Jnci-J Natl Cancer I"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.04.020","article-title":"Microenvironment determines lineage fate in a human model of leukemia","volume":"13","author":"Wei","year":"2008","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29382","article-title":"CRISPR screens in mechanism and target discovery for AML","volume":"10","author":"Lin","year":"2024","journal-title":"Heliyon"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100654","DOI":"10.1016\/j.crmeth.2023.100654","article-title":"Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling","volume":"3","author":"Andersen","year":"2023","journal-title":"Cell Rep Methods"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Lane","year":"2009","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"17179","DOI":"10.1038\/s41598-025-01711-x","article-title":"Leukemia cells remodel bone marrow stromal cells to generate a protumoral microenvironment via the S100A8-NOX2-ROS signaling pathway","volume":"15","author":"Gu","year":"2025","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115151","article-title":"Bone marrow mesenchymal stromal cells support translation in refractory acute myeloid leukemia","volume":"44","author":"Lisi-Vega","year":"2025","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-567065","article-title":"HIF-1\u03b1 can act as a tumor suppressor gene in murine acute myeloid leukemia","volume":"124","author":"Velasco-Hernandez","year":"2014","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","article-title":"The bone marrow microenvironment in acute myeloid leukemia: emerging roles in leukemogenesis, treatment resistance and immunotherapy","volume":"11","author":"Poitvitayaporn","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.635189","article-title":"Vascular niches in hematological Malignancies","volume":"9","author":"Paczulla","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"115151","DOI":"10.1016\/j.celrep.2024.115151","article-title":"Bone marrow mesenchymal stromal cells support translation in refractory AML","volume":"44","author":"Lisi-Vega","year":"2025","journal-title":"Cell Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111965","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2020.09.001","article-title":"Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defenses","volume":"136","author":"Forte","year":"2020","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012615-044414","article-title":"Hematopoietic stem cell niche in health and disease","volume":"11","author":"Hoggatt","year":"2016","journal-title":"Annu Rev Pathol-Mech"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1805440115","article-title":"In vitro biomimetic engineering of a human hematopoietic niche with functional properties","volume":"115","author":"Bourgine","year":"2018","journal-title":"P Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107388","article-title":"Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations","volume":"134","author":"Patel","year":"2023","journal-title":"Leukemia Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/onco5040051","article-title":"Rebuilding the marrow in vitro: translational advances in the 3D modeling of blood cancers","volume":"5","author":"Silvestri","year":"2025","journal-title":"Onco"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-0199","article-title":"Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic Malignancies","volume":"13","author":"Khan","year":"2023","journal-title":"Cancer Discov"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122719","article-title":"Microenvironment matters: in vitro 3D bone marrow niches differentially modulate survival, phenotype and drug responses of acute myeloid leukemia cells","volume":"312","author":"Cheung","year":"2025","journal-title":"Biomaterials"},{"key":"B42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40824-023-00457-9","article-title":"Fabrication of a three-dimensional bone marrow niche-like acute myeloid leukemia disease model by an automated and controlled process using a robotic multicellular bioprinting system","volume":"27","author":"Alhattab","year":"2023","journal-title":"Biomater Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba5536","article-title":"Leukemia-on-a-chip: dissecting the chemoresistance mechanisms in B cell acute lymphoblastic leukemia bone marrow niche","volume":"6","author":"Ma","year":"2020","journal-title":"Sci Adv"},{"key":"B44","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s42003-025-08137-1","article-title":"A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development","volume":"8","author":"Koenig","year":"2025","journal-title":"Commun Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41420-025-02505-w","article-title":"Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: a cutting-edge tool for advancing personalised treatments","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036831","article-title":"Novel quinazolinone MJ-29 triggers endoplasmic reticulum stress and intrinsic apoptosis in murine leukemia WEHI-3 cells and inhibits leukemic mice","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS One"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007250","article-title":"In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies","volume":"6","author":"Mercier","year":"2022","journal-title":"Blood Adv"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.854973","article-title":"Murine models of acute myeloid leukemia","volume":"12","author":"Kurtz","year":"2022","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.08.031","article-title":"FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia","volume":"12","author":"Lee","year":"2007","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological Malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: From mechanisms to therapy (vol 41, pg 49, 2014)","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011619","article-title":"MICA\/B antibody induces macrophage-mediated immunity against acute myeloid leukemia","volume":"139","author":"Alves da Silva","year":"2022","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2024.104256","article-title":"Immune control in acute myeloid leukemia","volume":"138","author":"Straube","year":"2024","journal-title":"Exp Hematol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03374-0","article-title":"FLT3-targeted treatment for acute myeloid leukemia","volume":"116","author":"Arai","year":"2022","journal-title":"Int J Hematol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259457","article-title":"Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model","volume":"106","author":"Stroopinsky","year":"2021","journal-title":"Haematologica"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1350","article-title":"Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region","volume":"25","author":"Ishikawa","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/s41467-022-29304-6","article-title":"Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells","volume":"13","author":"Kawashima","year":"2022","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.031","article-title":"Functional heterogeneity of genetically defined subclones in acute myeloid leukemia","volume":"25","author":"Klco","year":"2014","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2174\/1389201016666150817095703","article-title":"Xenograft models of primary acute myeloid leukemia for the development of imaging strategies and evaluation of novel targeted therapies","volume":"17","author":"Gelebart","year":"2016","journal-title":"Curr Pharm Bio\/Technol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ccell.2016.03.008","article-title":"The public repository of xenografts enables discovery and randomized phase II-like trials in mice (vol 29, pg 574, 2016)","volume":"30","author":"Townsend","year":"2016","journal-title":"Cancer Cell"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/cancers15112944","article-title":"CAR-T cells immunotherapies for the treatment of acute myeloid leukemia-recent advances","volume":"15","author":"Zarychta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-1077","article-title":"IMGN779, a novel CD33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML","volume":"17","author":"Kovtun","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T cells for acute myeloid leukemia: State of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clim.2009.12.008","article-title":"Parameters for establishing humanized mouse models to study human immunity: Analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the \u03b3 mutation","volume":"135","author":"Brehm","year":"2010","journal-title":"Clin Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.113852","article-title":"A hostel for the hostile: the bone marrow niche in hematologic neoplasms","volume":"100","author":"Krause","year":"2015","journal-title":"Haematologica"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/wdev.400","article-title":"Zebrafish models of acute leukemias: Current models and future directions","volume":"10","author":"Molina","year":"2020","journal-title":"WIREs Dev Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112944","article-title":"The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft platform for precision medicine and preclinical research","volume":"8","author":"DeBord","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.1038\/s41598-021-85141-5","article-title":"Targeted therapy of human leukemia xenografts in immunodeficient zebrafish","volume":"11","author":"Somasagara","year":"2021","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030567","article-title":"A preclinical embryonic zebrafish xenograft model to investigate CAR T cells in vivo","volume":"12","author":"Pascoal","year":"2020","journal-title":"Cancers"},{"key":"B76","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4049\/immunohorizons.2400059","article-title":"Chick embryo chorioallantoic membrane as a platform for assessing the in vivo efficacy of CAR T-cell therapy in solid tumors","volume":"8","author":"Nipper","year":"2024","journal-title":"ImmunoHorizons"},{"key":"B77","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","article-title":"Humanized mouse models for immuno-oncology research","volume":"20","author":"Chuprin","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11061548","article-title":"A comparison of lymphoid and myeloid cells derived from human hematopoietic stem cells xenografted into NOD-derived mouse strains","volume":"11","author":"Gutierrez-Barbosa","year":"2023","journal-title":"Microorganisms"},{"key":"B79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-0716-2160-8_5","article-title":"Development of humanized mouse models for studying human NK cells in health and disease","volume":"2463","author":"Shan","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00099-9","article-title":"Cancer cell therapies: the clinical trial landscape","volume":"19","author":"Yu","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-676452","article-title":"Peripheral blood CD34 cells efficiently engraft human cytokine knock-in mice","volume":"128","author":"Saito","year":"2016","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200045R","article-title":"Enhanced development of functional human NK cells in NOD-scid-IL2rg(null) mice expressing human IL15","volume":"36","author":"Aryee","year":"2022","journal-title":"FASEB J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0416-z","article-title":"Humanized immune system mouse models: progress, challenges and opportunities","volume":"20","author":"Allen","year":"2019","journal-title":"Nat Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201848001","article-title":"Accelerated thymopoiesis and improved T-cell responses in HLA-A2\/-DR2 transgenic BRGS-based human immune system mice","volume":"49","author":"Masse-Ranson","year":"2019","journal-title":"Eur J Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-pathol-052016-100332","article-title":"Humanized mouse models of clinical disease","volume":"12","author":"Walsh","year":"2017","journal-title":"Annu Rev Pathol: Mech Dis Vol 12"},{"key":"B87","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3324\/haematol.2014.115212","article-title":"Humanized hemato-lymphoid system mice","volume":"101","author":"Theocharides","year":"2016","journal-title":"Haematologica"},{"key":"B88","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41419-025-07861-0","article-title":"Humanized mouse models in MDS","volume":"16","author":"Munteanu","year":"2025","journal-title":"Cell Death Dis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B90","doi-asserted-by":"publisher","first-page":"101520","DOI":"10.1016\/j.gendis.2025.101520","article-title":"Patient-derived xenograft models: Current status, challenges, and innovations in cancer research","volume":"12","author":"Liu","year":"2025","journal-title":"Genes Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40164-025-00726-4","article-title":"Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting","volume":"14","author":"Oca\u00f1a-Cara","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.10.007","article-title":"Combinatorial antigen targeting strategies for acute leukemia: application in myeloid Malignancy","volume":"24","author":"Atilla","year":"2022","journal-title":"Cytotherapy"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.052","article-title":"CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes","volume":"33","author":"Khalifeh","year":"2025","journal-title":"Mol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: Challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Yu","year":"2019","journal-title":"biomark Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/imed.1031","article-title":"Chimeric antigen receptor-engineered adoptive cell therapy for AML: current status and future perspectives","volume":"2","author":"Huang","year":"2022","journal-title":"Immunomedicine"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1186\/s12967-025-07151-5","article-title":"CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ady7328","article-title":"Cross-species cellular mapping and humanization of Fc\u03b3 receptors to advance antibody modeling","volume":"11","author":"Van Damme","year":"2026","journal-title":"Sci Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.3390\/cancers13246258","article-title":"Harnessing macrophages through the blockage of CD47: implications for acute myeloid leukemia","volume":"13","author":"Melo Garcia","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","article-title":"Biomarkers as targets for CAR-T\/NK cell therapy in AML","volume":"11","author":"Shao","year":"2023","journal-title":"biomark Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867103","article-title":"Leukemia\u2019s next top model? Syngeneic models to advance adoptive cellular therapy","volume":"13","author":"Zoine","year":"2022","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02897-5","article-title":"Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies","volume":"70","author":"Bareham","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.553362","article-title":"Humanized mouse as a tool to predict immunotoxicity of human biologics","volume":"11","author":"Yong","year":"2020","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143180","article-title":"Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a growth factor independence 1 dependent manner","volume":"101","author":"Al-Matary","year":"2016","journal-title":"Haematologica"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf8522","article-title":"M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism","volume":"9","author":"Weinh\u00e4user","year":"2023","journal-title":"Sci Adv"},{"key":"B110","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","article-title":"Catch me if you can: how AML and its niche escape immunotherapy","volume":"36","author":"Tettamanti","year":"2022","journal-title":"Leukemia"},{"key":"B111","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbrc.2023.04.067","article-title":"Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells","volume":"662","author":"Flahou","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104231","article-title":"Natural killer cells at the forefront of cancer immunotherapy with immune potency, genetic engineering, and nanotechnology","volume":"193","author":"Pan","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191358","article-title":"Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models","volume":"13","author":"Otegbeye","year":"2018","journal-title":"PLoS One"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015474","article-title":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post\u2013allo-HSCT","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.643852","article-title":"Building the next generation of humanized hemato-lymphoid system mice","volume":"12","author":"Martinov","year":"2021","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model (vol 32, pg 364, 2014)","volume":"35","author":"Rongvaux","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahl\u00e9n","year":"2018","journal-title":"Ther Adv Vaccines Immunother"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e22995","DOI":"10.1096\/fj.202300040r","article-title":"Simultaneous evaluation of treatment efficacy and toxicity for bispecific T\u2010cell engager therapeutics in a humanized mouse model","volume":"37","author":"Yang","year":"2023","journal-title":"FASEB J"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02566-x","article-title":"Immune checkpoints regulate acute myeloid leukemia stem cells","volume":"39","author":"Reinhardt","year":"2025","journal-title":"Leukemia"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2025.08.003","article-title":"The immunotherapy landscape in AML: defining knowledge gaps toward rational combinatorial strategies","volume":"62","author":"Subklewe","year":"2025","journal-title":"Semin Hematol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-2063","article-title":"Frequency and dynamics of leukemia-initiating cells during short-term ex vivo culture informs outcomes in acute myeloid leukemia patients","volume":"76","author":"Griessinger","year":"2016","journal-title":"Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02326-3","article-title":"CXCR4 as a therapeutic target in acute myeloid leukemia","volume":"38","author":"Korbecki","year":"2024","journal-title":"Leukemia"},{"key":"B129","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jim.2015.04.020","article-title":"Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials \u2014 whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm","volume":"424","author":"Vessillier","year":"2015","journal-title":"J Immunol Methods"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1732193","article-title":"Perspective of using in vitro models to understand immunotherapy-induced cytokine release syndrome","volume":"16","author":"Perkins","year":"2025","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-025-01112-8","article-title":"Neurological complications of CAR T cell therapy for cancers","volume":"21","author":"Karschnia","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1871786\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:39:35Z","timestamp":1784007575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1871786\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":135,"alternative-id":["10.3389\/fimmu.2026.1871786"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1871786","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1871786"}}